• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

Overseas is the answer?... Yuhan Corp. · GC Bio, etc. Pharmabio industry, Q3 profits soar on 'global' ride

김나영 기자

steaming@fntimes.com

기사입력 : 2024-11-05 10:15

PharmaBio Q3 earnings, Was ‘Global’ the Key?
Yuhan Corp., GC Bio, Daewoong, CKD Bio grow side by side
Hanmi Pharm’s sales and operating profit decrease… China’s decline is growing

Headquarters of Yuhan Corporation, GC Bio, Daewoong Pharmaceutical, Chong Kun Dang, and Hanmi Pharmaceutical. /Photo courtesy of each company

Headquarters of Yuhan Corporation, GC Bio, Daewoong Pharmaceutical, Chong Kun Dang, and Hanmi Pharmaceutical. /Photo courtesy of each company

이미지 확대보기
[Korea Financial Times, Kim Nayoung] Major domestic pharmaceutical companies achieved large profits in the global market in the third quarter. They seem to have found a boost from overseas, overcoming concerns that protracted political conflicts could threaten the industry. On the other hand, drugmakers with weak overseas sales saw their overall profits deteriorate.

According to our report on the 4th, traditional pharmaceutical companies such as Yuhan Corporation, GC Biopharma, Daewoong Pharmaceutical, and Chong Kun Dang have shown performance overseas and received favorable report cards (tentative) for the third quarter of this year.

First, Yuhan Corporation benefited most from the ‘power of globalization’. The company's third-quarter revenue and operating profit were KRW 116.3 billion and KRW 47.6 billion, respectively, up 24.8 % and 689.9 % year-on-year. Both revenue and operating profit were the highest ever recorded on a quarterly basis.

This was largely due to lung cancer drug 'Leclaza'. The company received a $60 million (about KRW 804 million) milestone payment from Janssen Biotech in August after successfully securing U.S. Food and Drug Administration (FDA) approval for 'Leclaza'. The company had previously signed a $1.255 billion (KRW 1.6 trillion) deal in 2018 to transfer 'Leclaza' to Janssen. Even though the performance of its existing main business, prescription drugs, was sluggish, 'Leclaza'’s overseas earnings filled the gap.

GC Biopharma, which struggled in the first half of the year, also shed its deficit tag with the US launch of its blood product ‘Aliglo’. GC Biopharma’s sales (consolidated basis) in the third quarter of this year increased 5.8% year-on-year to KRW 464.9 billion. Operating profit for the same period increased 20.8% to KRW 39.6 billion.

GC Biopharma was unable to avoid deficits in the first half of the year due to the medical strike and the launch of Aliglo. However, it seems that it has entered a period of full-scale performance recovery as the sales of Aliglo, which received FDA approval in July and settled in the US, are reflected starting in the third quarter.

Daewoong Pharmaceutical’s sales and operating profit also jumped significantly. The company’s sales and operating profit (separate basis) in the third quarter increased 4.26% and 20.32% year-on-year to KRW 315.9 billion and KRW 41.1 billion, respectively.

The botulinum toxin product ‘Nabota’ and the gastroesophageal reflux treatment ‘Pexuclu’ played a leading role. Nabota is so popular that it is ranked second in the botulinum toxin market in the United States. The 34th domestic new drug, 'Pexuclu', was also launched simultaneously in three Central and South American countries, Mexico, Chile, and Ecuador, in August. At the time, Park Sung-soo, CEO of Daewoong Pharmaceutical, expressed a strong will to advance into the global market for Pexuclu, saying, “We will introduce it to 100 countries by 2027.”

Chong Kun Dang recorded separate sales of KRW 408.5 billion and operating profit of KRW 25.2 billion in the third quarter of this year. Sales increased by 3.1% year-on-year, but operating profit decreased by 52.5%. This is because the contract for HK Innoen’s gastroesophageal reflux disease treatment ‘K-Cap’, which records annual prescriptions of KRW 100 billion, has ended.

What is notable is the growth of its affiliate Chong Kun Dang Bio. Chong Kun Dang Bio recorded sales of KRW 43.9 billion and operating profit of KRW 2.6 billion in the third quarter, successfully turning a profit compared to the same period last year. The company has been consistently in the black since the first quarter of this year, and this is due to the expansion of exports of raw pharmaceutical ingredients and finished products.

Hanmi Pharmaceutical is the only one among the top five pharmaceutical companies to see a decrease in both sales and operating profit compared to the same period last year. Consolidated sales for the third quarter of this year decreased by 0.7% year-on-year to KRW 362.1 billion. Operating profit fell 11.4% to KRW 51 billion.

In particular, the decline of Beijing Hanmi Pharmaceutical, a local Chinese corporation, is notable. Beijing Hanmi Pharmaceutical recorded sales of KRW 84.3 billion and operating profit of KRW 15 billion in the third quarter. These figures are 9.7% and 42.4% decreases, respectively, from the same period last year. ‘The number of business days decreased, and physical environmental factors such as natural disasters in China slowed down sales,’ said a Hanmi Pharmaceutical representative.

In addition, they added that they plan to rebound by targeting the global market. Hanmi Pharmaceutical emphasized, “We will present about 10 innovative new drug research results for cancer, obesity, and rare diseases at various global academic conferences in the second half of this year,” and “In particular, we plan to unveil a ‘new concept obesity treatment’ that simultaneously achieves weight loss and muscle gain for the first time at the American Society for the Study of Obesity in November.”

Meanwhile, according to the Korea Biotechnology Industry Organization, the global pharmaceutical market size as of last year was 1.61 trillion dollars (approximately KRW 2,150 trillion). In comparison, Korea’s market size was only 23 billion dollars (KRW 29.86 trillion). The U.S. accounted for more than 40% of the global market at 600 billion dollars (KRW 825.3 trillion).

A pharmaceutical and biotechnology industry official said, “The domestic pharmaceutical market is already saturated, and it is also very small compared to the U.S. in terms of size,” and “For continued growth, targeting global markets such as the U.S. is essential.”

Kim Nayoung, Korea Finacial Times (steaming@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

기자의 기사 더보기 전체보기

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 Hanwha Solutions’ Pretax Profit Owes to Asset Sale, Not Core Business Hanwha Solutions’ third-quarter pretax profit turned positive, but the driver was not its core business. It was a single asset sale. The company sold intangible assets with a book value of KRW 12.5 billion and booked a gain of KRW 199.7 billion. Without that gain, this year’s third quarter would show a pretax loss of KRW 176.3 billion.The proceeds from the disposal differ by only KRW 0.8 billion from the amount of fixed assets Hanwha Solutions sold to TransGrid Energy, a Hanwha Group affiliate, over the same period. TransGrid Energy is a subsidiary of a joint venture in which Hanwha Solution 2 Lotte Chemical Pays Down JV Debt With KRW 600 Billion as Its Own Loans Get a Three-Year Reprieve Lotte Chemical contributed KRW 600 billion to help its joint venture H&L Advanced repay existing borrowings. But it has also taken on an impairment loss on its JV shares and faces additional funding support obligations. The value of the shares recognized in the merger-date accounting was less than half the per-share value assessed by an external valuation firm when the merger ratio was set. While pouring large sums into improving the JV’s finances, Lotte Chemical itself has agreed with its creditors to a three-year deferral of repayment on its covenant debt.According to the Financial Supe 3 S-Oil Hits Record Profit, but Shares Sink 40% as Shaheen Bet Looms S-Oil posted record quarterly operating profit in the third quarter of this year, yet its share price has fallen about 40% from its peak.Despite strong results in refining and lubricants, earnings are expected to decline next year. The company also faces the task of proving the profitability of the petrochemical project Shaheen, in which it has invested more than KRW 9 trillion, amid concerns over oversupply.S-Oil reported third-quarter revenue of KRW 11.9687 trillion and operating profit of KRW 1.4067 trillion. Operating profit surged 514% from a year earlier and beat the market consensus by
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[카드뉴스] 성북동 언덕길, 만해의 집을 만나다
[카드뉴스] 약재 향 따라 걷는 서울약령시
[그래픽 뉴스] ‘순대’가 경제용어라고? 순(純)대외자산, 한국의 진짜 해외자산은 얼마일까?
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'

FT도서

더보기